Shows improvement in overall survival in HER2-positive breast cancer, suggesting a crucial treatment advancement.
The addition of trastuzumab to paclitaxel after doxorubicin and cyclophosphamide in early-stage HER2-positive breast cancer results in a substantial and durable improvement in survival as a result of a sustained marked reduction in cancer recurrence.
No takes yet. Share an insight, caveat, or question.
Perez et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: